Enlivex Therapeutics Ltd.
ENLVHealthcare|Biotechnology|IL
$1.27
+0.00 (+0.00%)
Tangible Book / Share
$2661.47
Graham Number
$18359.01
Cash / Share
$5.34
Financials
Financial Snapshot
Market Cap
$21.4M
Enterprise Value
$33.1M
Revenue (TTM)
$0.00
Net Income (TTM)
$4.11B
Cash & Investments
$5.5M
Net Cash
-$11.7M
Free Cash Flow (TTM)
-$16.2M
Operating CF (TTM)
-$15.8M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$5.5M
Quarterly Burn
$4.0M
Monthly Burn
$1.3M
Est. Runway
~1.4 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $9.9M | $3.5M | $9.8M | $12.0M | $35.7M | $84.1M | $50.2M | $27.3M | $23.6M | $5.9M | $5.5M | |
| Operating Cash Flow | -$15.5M | -$6.4M | -$3.2M | -$7.0M | -$11.0M | -$17.5M | -$24.0M | -$23.5M | -$13.0M | -$10.4M | -$15.8M | |
| Free Cash Flow | -$15.5M | -$6.4M | -$3.6M | -$7.2M | -$12.0M | -$19.2M | -$32.1M | -$23.8M | -$13.1M | -$10.5M | -$16.2M | |
| Capital Expenditure | -$18.0K | -$2.0K | -$461.0K | -$193.0K | -$1.0M | -$1.6M | -$8.1M | -$236.0K | -$103.0K | -$68.0K | -$41.9K | |
| Financing Cash Flow | $6.1M | $8.1M | $5.2M | $8.3M | $33.1M | $61.0M | $150.0K | $360.0K | $6.5M | $10.4M | $33.9M |
R&D Spending
R&D (TTM)
$10.7M
R&D Intensity
—
R&D Growth vs Prior
+20.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $2.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $8.9M | $2.5M | $4.1M | $5.7M | $6.1M | $12.9M | $18.7M | $19.2M | $10.1M | $8.9M | $10.7M | |
| R&D % of Revenue | — | — | — | — | 267.3% | — | — | — | — | — | — | |
| SG&A | $7.0M | $3.4M | $1.0M | $2.8M | $3.6M | $6.2M | $6.7M | $6.1M | $4.9M | $5.7M | $9.7M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $2.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $25.0K | $12.0K | $121.0K | $297.0K | $286.0K | $546.0K | $777.0K | $835.0K | $545.0K | $332.0K | $214.0K | |
| Gross Profit | -$25.0K | -$12.0K | -$121.0K | -$297.0K | -$286.0K | -$546.0K | -$777.0K | -$835.0K | -$545.0K | -$332.0K | -$214.0K | |
| R&D | $8.9M | $2.5M | $4.1M | $5.7M | $6.1M | $12.9M | $18.7M | $19.2M | $10.1M | $8.9M | $10.7M | |
| SG&A | $7.0M | $3.4M | $1.0M | $2.8M | $3.6M | $6.2M | $6.7M | $6.1M | $4.9M | $5.7M | $9.7M | |
| Operating Income | -$13.9M | -$5.8M | -$5.3M | -$8.6M | -$9.8M | -$19.3M | -$25.8M | -$29.4M | -$15.5M | -$15.0M | -$20.6M | |
| Interest Expense | $0.00 | $0.00 | $3.0K | $7.0K | $6.0K | $328.0K | $5.3M | $14.0K | $13.0K | $13.0K | $1.3M | |
| Pretax Income | -$15.8M | -$5.9M | -$4.2M | -$9.4M | -$11.8M | -$14.5M | -$31.1M | -$29.1M | -$15.0M | $1.62B | $5.35B | |
| Net Income | -$16.0M | -$5.9M | -$4.2M | -$9.4M | -$11.8M | -$14.5M | -$31.1M | -$29.1M | -$15.0M | $1.24B | $4.11B | |
| EPS (Diluted) | -9669.60 | -3331.20 | -2551.20 | -280.80 | -252.00 | -129.60 | -554.40 | -374.40 | -175.20 | 6115.20 | 8600.32 | |
| EBITDA | -$13.9M | -$5.9M | -$5.2M | -$8.4M | -$9.5M | -$18.7M | -$25.0M | -$28.2M | -$14.5M | -$14.7M | -$19.9M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.07 | 0.08 | 0.08 | 0.09 | 0.20 | 1.21 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.9M | $3.5M | $9.7M | $3.9M | $5.7M | $11.2M | $49.9M | $813.0K | $3.3M | $2.0M | $5.5M | |
| Short-Term Investments | $3.0M | $0.00 | $40.0K | $8.1M | $30.0M | $72.9M | $299.0K | $26.5M | $20.2M | $3.9M | $0.00 | |
| Total Current Assets | $10.5M | $3.6M | $10.3M | $16.4M | $38.1M | $86.4M | $52.3M | $33.8M | $26.0M | $1.74B | $3.75B | |
| Total Assets | $10.6M | $3.6M | $11.0M | $17.6M | $40.4M | $95.1M | $67.6M | $36.8M | $27.7M | $2.33B | $4.90B | |
| Total Current Liabilities | $1.9M | $460.0K | $1.1M | $6.0M | $4.4M | $4.7M | $6.6M | $6.1M | $3.8M | $9.0M | $31.4M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.9M | $460.0K | $1.3M | $6.3M | $4.9M | $10.1M | $10.8M | $6.7M | $4.1M | $392.1M | $1.00B | |
| Stockholders' Equity | $8.7M | $3.2M | $9.7M | $11.3M | $35.5M | $85.0M | $56.8M | $30.1M | $23.6M | $1.93B | $3.90B | |
| Retained Earnings | -$39.8M | -$45.8M | -$16.3M | -$25.7M | -$37.5M | -$52.0M | -$83.0M | -$112.1M | -$127.1M | $1.11B | $3.06B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.5M | -$6.4M | -$3.2M | -$7.0M | -$11.0M | -$17.5M | -$24.0M | -$23.5M | -$13.0M | -$10.4M | -$15.8M | |
| Capital Expenditure | -$18.0K | -$2.0K | -$461.0K | -$193.0K | -$1.0M | -$1.6M | -$8.1M | -$236.0K | -$103.0K | -$68.0K | -$41.9K | |
| Free Cash Flow | -$15.5M | -$6.4M | -$3.6M | -$7.2M | -$12.0M | -$19.2M | -$32.1M | -$23.8M | -$13.1M | -$10.5M | -$16.2M | |
| Investing Cash Flow | $9.0M | $3.0M | -$533.0K | -$6.4M | -$21.0M | -$38.4M | $62.5M | -$26.0M | $9.1M | -$1.3M | -$14.5M | |
| Financing Cash Flow | $6.1M | $8.1M | $5.2M | $8.3M | $33.1M | $61.0M | $150.0K | $360.0K | $6.5M | $10.4M | $33.9M | |
| Issuance of Stock | $6.1M | $8.1M | $5.2M | $7.7M | $24.5M | $53.2M | $150.0K | $360.0K | $6.5M | $10.4M | $10.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $700.0K | $408.0K | $1.0M | $810.0K | $670.0K | $2.9M | $2.7M | $2.0M | $2.1M | $1.8M | $1.2M | |
| Net Change in Cash | -$415.0K | -$3.3M | $731.0K | -$4.3M | $1.5M | $4.6M | $38.7M | -$49.1M | $2.5M | -$1.4M | -$2.4M |
Dilution Tracker
Shares outstanding grew 268.3% over 5 years — significant dilution
Shares Outstanding
17M
5-Year Share Growth
+268.3%
Stock Issuance (TTM)
$10.8M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.07 | 0.08 | 0.08 | 0.09 | 0.20 | 1.21 | |
| Change vs Prior % | — | 7.7% | 7.7% | 1776.1% | 52.3% | 35.6% | 3.0% | 1.0% | 10.4% | 136.4% | 498.0% | |
| Stock Issuance | $6.1M | $8.1M | $5.2M | $7.7M | $24.5M | $53.2M | $150.0K | $360.0K | $6.5M | $10.4M | $10.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $700.0K | $408.0K | $1.0M | $810.0K | $670.0K | $2.9M | $2.7M | $2.0M | $2.1M | $1.8M | $1.2M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | -12.6% | — | — | — | — | — | — | |
| Operating Margin % | — | — | — | — | -429.7% | — | — | — | — | — | — | |
| Net Margin % | — | — | — | — | -519.3% | — | — | — | — | — | — | |
| EBITDA Margin % | — | — | — | — | -417.2% | — | — | — | — | — | — | |
| FCF Margin % | — | — | — | — | -528.2% | — | — | — | — | — | — | |
| ROE % | -184.2% | -188.0% | -43.7% | -83.2% | -33.3% | -17.0% | -54.6% | -96.6% | -63.6% | 63.9% | 211.0% | |
| ROA % | -150.7% | -164.1% | -38.4% | -53.4% | -29.3% | -15.2% | -45.9% | -78.9% | -54.2% | 53.1% | 83.8% | |
| ROIC % | -160.3% | -185.0% | -53.5% | -73.6% | -27.0% | -21.2% | -41.8% | -94.5% | -64.4% | -0.5% | -0.3% | |
| R&D / Revenue % | — | — | — | — | 267.3% | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -47.1% | 52.0% | -908.3% | -145.5% | 3.7% | -90.9% | -42.3% | -7.5% | 34.7% | 39.1% | |
| Operating Income | 9.9% | 58.1% | 9.4% | -62.7% | -13.5% | -97.1% | -33.7% | -13.9% | 47.1% | 3.5% | |
| Net Income | -4.3% | 62.9% | 28.6% | -121.2% | -26.0% | -22.4% | -114.7% | 6.4% | 48.3% | 8329.2% | |
| EPS (Diluted) | 6.7% | 65.5% | 23.4% | 89.0% | 10.3% | 48.6% | -327.8% | 32.5% | 53.2% | 3590.4% | |
| Operating Cash Flow | -16.9% | 59.0% | 50.2% | -122.7% | -56.3% | -59.4% | -36.5% | 1.8% | 44.7% | 19.9% | |
| Free Cash Flow | -16.6% | 59.0% | 43.0% | -99.7% | -66.2% | -59.4% | -67.3% | 25.9% | 44.8% | 20.0% | |
| R&D Expense | 15.4% | -71.7% | 64.2% | 38.5% | 6.3% | 111.6% | 45.1% | 2.9% | -47.4% | -11.9% | |
| SG&A Expense | -10.2% | -50.8% | -69.6% | 163.4% | 31.0% | 73.2% | 7.4% | -8.4% | -20.0% | 15.7% | |
| Total Assets | -48.2% | -65.9% | 204.6% | 59.1% | 129.8% | 135.8% | -28.9% | -45.6% | -24.8% | 8304.7% | |
| Book Value / Share | -56.6% | -65.1% | 175.8% | -93.8% | 106.6% | 76.7% | -35.1% | -47.6% | -29.0% | 3582.4% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 65.0% | 2858.6% | -19.3% | -78.7% | -48.3% | 20.0% | |
| Diluted Shares | 11.8% | 7.7% | 7.7% | 1776.1% | 52.3% | 35.6% | 3.0% | 1.0% | 10.4% | 136.4% |
Valuation
P/E (TTM)0.00
P/S0.00
P/B0.00
10Y Low / Med / High0.02 / 1.67 / 6.43
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$2661.47
Net Current Assets / Share
$163.34
Graham Number
$18359.01
Cash / Share
$5.34
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1.03 | -1.27 | -0.58 | -7.17 | -8.03 | -11.57 | -1.71 | -1.73 | -1.60 | 0.03 | 0.00 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 48.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 1.90 | 2.40 | 0.29 | 6.43 | 3.13 | 1.31 | 1.28 | 1.67 | 1.02 | 0.02 | 0.00 | |
| EV/EBITDA | -0.69 | -0.69 | 1.33 | -8.17 | -11.11 | -5.68 | -1.09 | -1.78 | -1.47 | -2.10 | -1.66 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 46.35 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
1.78
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$3.7M | -$679.0K | -$45.7M |
| EPS | $-18.40 | $-3.36 | $-226.22 |
| # Analysts (EPS) | 1 | 1 | 1 |